Combined potential of SGLT2i and GLP1 RA mechanisms in organ protection

Czech version

Authors: Matej Samoš
Authors‘ workplace: I. interná klinika JLF UK a UNM, Martin
Published in: Forum Diab 2025; 14(2): 107-111
Category: Review Article

Overview

Sodium glucose co-transporter 2 inhibitors (SGLT2i) and glucagon like peptide 1 receptor agonists (GLP-1 RA) have significantly changed the treatment of type 2 diabetes (T2D), obesity and their complications. Beyond glycemic control, these agents offer cardiorenal protection acting multi-systemically throughout hemodynamics, metabolism, inflammation and cellular endurance. This article summarizes the mechanisms and clinical evidence regarding the synergy in benefits on cardiovascular, renal, liver, adipose and central nervous system benefits of these agents.

Keywords:

GLP-1 RA – organ protection – cardiorenal damage – SGLT2i

Sources

Vale C, Lourenço IM, Jordan G et al. Early combination therapy with SGLT2i and GLP-1 RA or dual GIP/GLP-1 RA in type 2 diabetes. Diabetes Obes Metab 2025; 27(2): 468–481. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.16077>.

Perkovic V, Jardine MJ, Neal B et al. [CREDENCE Trial Investigators]. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380(24): 2295–2306. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1811744>.

Heerspink HJL, Stefánsson BV, Correa-Rotter R et al. [DAPA-CKD Trial Committees and Investigators]. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020; 383(15): 1436–1446. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2024816>.

Herrington WG, Staplin N, Wanner C et al. [EMPA-KIDNEY Collaborative Group]. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2023; 388(2): 117–127. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2204233>.

Gerstein HC, Colhoun HM, Dagenais GR et al. [REWIND Investigators]. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet 2019; 394(10193): 131–138. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(19)31150-X>.

KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. [Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group]. Kidney Int 2024; 104(4 Suppl): S117–S314. Dostupné z DOI: <http://dx.doi.org/10.1016/j.kint.2023.10.018>.

Perkovic V, Tuttle KR, Rossing P et al. [FLOW Trial Committees and Investigators]. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024; 391(2): 109–121. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2403347>.

Apperloo EM, Gorriz JL, Soler MJ et al. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. Nat Med 2025; 31(1): 278–285. Dostupné z DOI: <http://dx.doi.org/10.1038/s41591–024–03327–6>.

Hasan I, Rashid T, Jaikaransingh V et al. SGLT2 inhibitors: Beyond glycemic control. J Clin Transl Endocrinol 2024; 35 : 100335. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jcte.2024.100335>.

Dimitriadis K, Adamopoulou E, Pyrpyris N et al. The effect of SGLT2 inhibitors on the endothelium and the microcirculation: from bench to bedside and beyond. Eur Heart J Cardiovasc Pharmacother 2023; 9(8): 741–757. Dostupné z DOI: <http://dx.doi.org/10.1093/ehjcvp/pvad053>.

Greco EV, Russo G, Giandalia A et al. GLP-1 Receptor Agonists and Kidney Protection. Medicina (Kaunas) 2019; 55( 6): 233. Dostupné z DOI: <http://dx.doi.org/10.3390/medicina55060233>.

Hogan AE, Davis C, Jenkins BJ et al. Repurposing metabolic drugs as anti-inflammatory agents. Trends Endocrinol Metab 2025; 13: S1043–2760(25)00149–3. Dostupné z DOI: <http://dx.doi.org/10.1016/j.tem.2025.07.003>.

Ndumele CE, Neeland IJ, Tuttle KR et al. [American Heart Association]. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association. Circulation 2023; 148(20): 1636–1664. Dostupné z DOI: <http://dx.doi.org/10.1161/CIR.0000000000001186>.

Ghazal R, Wang M, Liu D et al. Cardiac Fibrosis in the Multi-Omics Era: Implications for Heart Failure. Circ Res 2025; 136(7): 773–802. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCRESAHA.124.325402>.

Xia D, Liu Y, Wu P et al. Current Advances of Mitochondrial Dysfunction and Cardiovascular Disease and Promising Therapeutic Strategies. Am J Pathol 2023; 193(10): 1485–1500. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ajpath.2023.06.013>.

Manolis AA, Manolis TA, Manolis AS. Neurohumoral Activation in Heart Failure. Int J Mol Sci 2023; 24(20): 15472. Dostupné z DOI: <http://dx.doi.org/10.3390/ijms242015472>.

Rolek B, Haber M, Gajewska M et al. SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain. SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain. J Cardiovasc Dev Dis 2023; 10(8): 322. Dostupné z DOI: <http://dx.doi.org/10.3390/jcdd10080322>.

Zou H, Zhou B, Xu G. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease. Cardiovasc Diabetol 2017; 16(1): 65. Dostupné z DOI: <http://dx.doi.org/10.1186/s12933–017–0547–1 >. Erratum in: Correction to: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease. Cardiovasc Diabetol 2018; 17(1): 38. Dostupné z DOI: <http://dx.doi.org/10.1186/s12933–018–0676–1>.

Wilcox T, De Block C, Schwartzbard AZ et al. Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar. J Am Coll Cardiol 2020; 75(16 ): 1956–1974. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2020.02.056 >. Erratum in: J Am Coll Cardiol 2020; 76(14): 1719–1722. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2020.08.023>.

Gourdy P, Darmon P, Dievart F et al. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2D). Cardiovasc Diabetol 2023; 22(1): 79. Dostupné z DOI: <http://dx.doi.org/10.1186/s12933–023–01798–4>.

Fralick M, Colacci M, Odutayo A et al. Lowering of hemoglobin A1C and risk of cardiovascular outcomes and all-cause mortality, a meta-regression analysis. J Diabetes Complications 2020; 34(11): 107704. Dostupné z DOI: <http://dx.doi.org/ 10.1016/j.jdiacomp.2020.107704>.

Goncalves E, Bell DSH. Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk. Diabetes Ther 2018; 9(3): 919–926. Dostupné z DOI: <http://dx.doi.org/10.1007/s13300–018–0420–6>.